{"entity":{"id":"nct06423911","kind":"trial","name":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","aka":[],"tldr":"A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.","summary":"Study of Olverembatinib (HQP1351) in Patients With CML-CP is a phase 3 interventional study registered as NCT06423911 by Ascentage Pharma Group Inc., with 333 participants planned, started 2024-02-05. Conditions listed: Chronic Myeloid Leukemia, CML, CML, Chronic Phase. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06423911","url":"https://clinicaltrials.gov/study/NCT06423911"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["olverembatinib"],"companies":["ascentage-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06423911","phase":"3","setting":"A Global, Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML-CP)","sponsor":"Ascentage Pharma Group Inc.","enrolled":333,"outcomes":[]},"route":"/trials/nct06423911/","neighbours":{"drug":[{"id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"}]}}